Direct oral anticoagulants (DOACs)

被引：9
|
作者：
Vazquez, Sara [1 ]
Rondina, Matthew T. [2 ,3 ,4 ]
机构：
[1] Univ Utah, Hlth Sci Ctr, Univ Healthcare Thrombosis Serv, Salt Lake City, UT USA
[2] Univ Utah, Dept Internal Med, Div Gen Internal Med, Salt Lake City, UT 84112 USA
[3] Univ Utah, Sch Med, Program Mol Med, Salt Lake City, UT USA
[4] George E Wahlen Salt Lake City VAMC, Dept Internal Med, Salt Lake City, UT USA
来源：
VASCULAR MEDICINE | 2015年 / 20卷 / 06期
关键词：
anticoagulants; apixaban; dabigatran; edoxaban; rivaroxaban; thrombosis; DVT; pulmonary embolism; PATIENT;
D O I：
10.1177/1358863X15600256
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
DOACs are a new group of blood-thinner medications that may have some advantages over warfarin. A health care provider will look at several different factors to help patients decide if a DOAC is a good choice. Patients taking DOACs should discuss medication changes, a plan for taking the DOAC before and after a surgery, and any bleeding side effects with their health care provider.
引用
收藏
页码：575 / 577
页数：3
相关论文
共 50 条
  • [1] Update on Direct Oral AntiCoagulants (DOACs)
    Koscielny, J.
    Rosenthal, C.
    von Heymann, C.
    PHLEBOLOGIE, 2018, 47 (03) : 137 - 145
  • [2] Clinical pearls: Laboratory assessments of direct oral anticoagulants (DOACS)
    Gosselin, Robert C.
    Douxfils, Jonathan
    Adcock, Dorothy
    HAMOSTASEOLOGIE, 2017, 37 (04): : 295 - 301
  • [3] Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?
    Lippi, Giuseppe
    Favaloro, Emmanuel J.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2015, 53 (02) : 185 - 197
  • [4] Update on Direct Oral AntiCoagulants (DOACs) Perioperative "switching", drug interactions and persistence
    Koscielny, Juergen
    Rosenthal, Christoph
    von Heymann, Christian
    HAMOSTASEOLOGIE, 2017, 37 (04): : 267 - 275
  • [5] Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review
    Adcock, D. M.
    Gosselin, R.
    THROMBOSIS RESEARCH, 2015, 136 (01) : 7 - 12
  • [6] Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations
    van Es, Nick
    Buller, Harry R.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2015, : 125 - 131
  • [7] Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges
    Favaloro, Emmanuel J.
    Pasalic, Leonardo
    Curnow, Jennifer
    Lippi, Giuseppe
    CURRENT DRUG METABOLISM, 2017, 18 (07) : 598 - 608
  • [8] Overview and Practical Application of Coagulation Assays in Managing Anticoagulation with Direct Oral Anticoagulants (DOACs)
    Rimsans J.
    Douxfils J.
    Smythe M.A.
    Gosselin R.C.
    Current Pharmacology Reports, 2020, 6 (5) : 241 - 259
  • [9] Reversal of Direct Oral Anticoagulants (DOACs) for Critical Bleeding or Urgent Procedures
    Goldin, Mark
    Tsaftaridis, Nikolaos
    Jnani, Jack
    Spyropoulos, Alex C.
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (03)
  • [10] Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs)
    Herink, Megan C.
    Zhuo, Yan F.
    Williams, Craig D.
    DeLoughery, Thomas G.
    DRUGS, 2019, 79 (15) : 1625 - 1634
12345